• Tuesday, May 28, 2024 @ 12:00 am

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications.

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights.
NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using its proprietary MATCH technology platform.

You may also be interested in